SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Evercore ISI Group Upgrades CymaBay Therapeutics to Outperform, Announces $15 Price Target

Evercore ISI Group analyst Josh Schimmer upgrades CymaBay Therapeutics (NASDAQ:CBAY) from In-Line to Outperform and announces $15 price target.

Benzinga · 05/12/2020 10:22

Evercore ISI Group analyst Josh Schimmer upgrades CymaBay Therapeutics (NASDAQ:CBAY) from In-Line to Outperform and announces $15 price target.